Every meal sends a wave of triglyceride-rich particles into your bloodstream. How quickly those particles are cleared depends partly on a protein called ApoC-III¹¹ ApoC-III
Apolipoprotein C-III — a small protein made in the liver that coats triglyceride-rich lipoproteins and inhibits the enzymes that break them down. The APOC3 gene encodes this protein, and its promoter contains an insulin response element — a molecular switch that normally lets insulin suppress ApoC-III production after eating. The rs2854116 variant disrupts that switch.

The Mechanism

The T-455C variant sits 455 base pairs upstream of the APOC3 coding sequence in a region of the promoter that binds insulin-signaling transcription factors. The common T allele preserves the insulin response element, allowing elevated postprandial insulin to suppress APOC3 transcription and keep ApoC-III levels low while fats are being cleared from the blood. The C allele disrupts this element, so the liver continues producing ApoC-III even when insulin signals "slow down." ApoC-III then inhibits lipoprotein lipase²² lipoprotein lipase
The enzyme that breaks down TG-rich particles on capillary walls throughout the body and hepatic lipase, slowing triglyceride clearance throughout the day.

The companion variant rs2854117 (C-482T) lies in the same promoter region and co-segregates with rs2854116 as part of the APOC3*222 haplotype. Together they account for most of the promoter-level regulation of APOC3 expression.

The Evidence

The landmark Petersen et al. study³³ Petersen et al. study
Petersen KF et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med, 2010 measured the metabolic consequences directly in 95 Asian Indian men. Variant allele (C allele) carriers had 60% higher fasting triglycerides, a 46% reduction in plasma triglyceride clearance rate, and roughly double the post-meal lipid burden compared to TT homozygotes. NAFLD prevalence was 38% among C carriers versus 0% among TT homozygotes (P<0.001). This was replicated in a 163-person non-Asian Indian validation cohort.

A 2003 coronary artery disease study⁴⁴ coronary artery disease study
Olivieri O et al. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res, 2003 of 873 patients found that the -455C allele multiplied coronary artery disease risk in an allele-dose fashion among individuals with metabolic syndrome, with CC carriers showing the highest ApoC-III and triglyceride levels.

A 2003 cohort study⁵⁵ 2003 cohort study
Waterworth DM et al. Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men. Biochim Biophys Acta, 2003 of 502 adults showed that CC homozygotes had approximately 23% lower early insulin secretion and ~10% higher circulating non-esterified fatty acids compared to TT homozygotes, confirming functional disruption of the insulin response element at both the hormonal and metabolic level.

Evidence is not uniformly consistent: a Dallas Heart Study analysis⁶⁶ Dallas Heart Study analysis
Kozlitina J et al. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology, 2011 in 2,497 participants found no significant association between the APOC3 promoter variants and hepatic fat or insulin resistance when analyzed in a multi-ethnic population without metabolic syndrome enrichment, suggesting the effect may be strongest in at-risk metabolic backgrounds.

Practical Actions

The key gene-diet interaction: Olivieri et al. 2005⁷⁷ Olivieri et al. 2005
Olivieri O et al. Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and T-455C APOC3 gene polymorphism in heart disease. Clin Chem, 2005 found that TT and CT carriers lowered ApoC-III progressively as omega-3 (EPA/DHA) intake increased — but CC homozygotes showed the opposite pattern, with elevated omega-3 levels paradoxically associated with higher ApoC-III. This means the standard advice to take fish oil for high triglycerides applies to TT/CT but may not work as expected for CC homozygotes.

A 2023 Japanese study⁸⁸ 2023 Japanese study
Yamamoto R et al. Nutrigenetic Interaction Between APOC3 Polymorphism and Fat Intake in People with NAFLD. Curr Dev Nutr, 2023 of 464 adults found that in TT individuals with NAFLD, fat intake above 25.4% of calories was associated with more severe fatty liver — a dietary threshold specific to TT carriers with established hepatic steatosis.

Postprandial management matters: because ApoC-III impairs TG clearance particularly after meals, strategies that reduce the size and frequency of fat boluses (smaller meals, lower glycemic load) should theoretically benefit C allele carriers by limiting the postprandial TG surge that overwhelmed clearance capacity.

Interactions

The rs2854116 variant co-segregates with rs2854117 (C-482T) as the APOC3*222 haplotype. Carrying both in combination (the full haplotype) may have stronger metabolic effects than either alone. The APOC3 locus also interacts with APOA5 (rs964184) in determining postprandial TG levels — both genes regulate TG-rich lipoprotein clearance through complementary mechanisms. Interaction with ANGPTL3 (rs11207977) is plausible given both proteins modulate lipoprotein lipase activity, though no compound action data are available for this specific combination.

Transthyretin (TTR) is a protein made primarily in the liver that carries thyroid hormone and vitamin A¹¹ thyroid hormone and vitamin A
TTR binds thyroxine (T4) and retinol-binding protein in plasma, serving as a transporter for these molecules throughout the body through the bloodstream. Normally, TTR exists as a stable four-molecule complex (tetramer). The Val30Met mutation — a single-letter change replacing valine with methionine at position 30 of the mature protein — destabilizes this tetramer, causing it to fall apart and refold into toxic amyloid fibrils that deposit in nerves, the heart, the eyes, and other organs. Without treatment, hereditary transthyretin amyloidosis (hATTR) with Val30Met is a fatal, progressive disease, typically killing within 10–12 years of symptom onset²² 10–12 years of symptom onset
Median untreated survival from stage 1 in the Portuguese natural history cohort was 11.6 years.

Val30Met is the most common amyloidogenic TTR mutation worldwide and the sole cause of epidemic-level amyloidosis in three endemic regions³³ three endemic regions
Founder effects explain the geographic clustering: separate ancestral mutations spread through isolated communities in northern Portugal, northern Sweden, and Japan: northern Portugal (where it accounts for ~92% of all hATTR cases), northern Sweden, and certain districts of Japan. The mutation is extremely rare in the general population — global carrier frequency is approximately 1 in 10,000 — but in endemic communities it may affect 1–5% of residents.

The Mechanism

The Val30Met substitution (c.148G>A, NM_000371.4) alters TTR's hydrophobic core⁴⁴ TTR's hydrophobic core
Valine has a smaller, branched side chain; methionine's longer, flexible thioether side chain disrupts the tightly packed core of each TTR monomer, reducing tetramer stability at physiological conditions. The mutant protein dissociates from the tetramer, misfolds into a β-sheet-rich amyloid conformation⁵⁵ β-sheet-rich amyloid conformation
Amyloid fibrils are long, insoluble protein strands that accumulate as protein plaques in tissues — they resist normal protein clearance mechanisms and progressively destroy the tissue they infiltrate, and deposits into the endoneurium of peripheral nerves (causing polyneuropathy), the myocardium (causing cardiomyopathy), the vitreous of the eye, and less commonly the kidneys, leptomeninges, and gastrointestinal tract.

The inherited TTR gene produces mutant protein lifelong. Because TTR is made almost entirely by the liver, liver transplantation historically halted the supply of new mutant TTR. Modern gene-silencing therapies (patisiran, inotersen) suppress TTR production from the liver non-surgically, and tetramer stabilizers (tafamidis) prevent the existing protein from falling apart.

The Evidence

The evidence base for Val30Met hATTR is among the strongest for any rare genetic disease, with three FDA-approved therapies supported by phase 3 randomized controlled trials.

Tafamidis (tetramer stabilizer): The ATTR-ACT trial⁶⁶ ATTR-ACT trial
Maurer et al., N Engl J Med, 2018 — 441 patients with transthyretin cardiomyopathy randomized 2:1 to tafamidis or placebo showed tafamidis reduced all-cause mortality by 30% (hazard ratio 0.70, 95% CI 0.51–0.96) and cardiovascular hospitalizations by 32% (relative risk 0.68) vs placebo over 30 months.

Patisiran (RNA interference): The APOLLO trial⁷⁷ APOLLO trial
Adams et al., N Engl J Med, 2018 — 225 patients with hATTR polyneuropathy demonstrated patisiran significantly reduced disease progression compared to placebo, with patients experiencing improvement in neuropathy impairment scores vs continued worsening in the placebo arm.

Inotersen (antisense oligonucleotide): The NEURO-TTR trial⁸⁸ NEURO-TTR trial
Benson et al., N Engl J Med, 2018 — 172 patients with hATTR polyneuropathy showed inotersen reduced neuropathy progression (mNIS+7) and improved quality of life vs placebo.

Natural history in the untreated era: A large Portuguese cohort study⁹⁹ Portuguese cohort study
Coelho et al., Amyloid, 2018 — N=3,160 patients followed through 2016 found median survival from stage 1 was only 11.6 years untreated. Tafamidis reduced mortality by 91% vs untreated in early-onset patients (<50 years). These findings establish that treatment within the first few years dramatically changes the disease course.

Penetrance and age of onset: Val30Met penetrance varies by geography and sex. In Sweden¹⁰¹⁰ Sweden
Gorram et al., Amyloid, 2021 — 114 Swedish families, 131 parent-offspring pairs, cumulative penetrance was <10% at age 40 but rose to 71% by age 90, with males showing significantly earlier onset. Average genetic anticipation was 11.7 years (disease appears earlier in each generation). In Portuguese families, onset typically occurs in the 30s–40s; in Sweden and France, late onset (>60 years) is more common.

Practical Actions

For TTR Val30Met carriers, the critical message is: early identification plus early treatment dramatically alters outcome. Symptoms typically begin insidiously — numbness and tingling in the feet, unexplained weight loss, carpal tunnel syndrome, or orthostatic hypotension. Carpal tunnel syndrome¹¹¹¹ Carpal tunnel syndrome
Bilateral carpal tunnel syndrome, especially in a young person, has been reported as the first manifestation of hATTR amyloidosis in ~50% of late-onset Val30Met cases appearing years before neuropathy onset is now recognized as an early warning sign.

Genotype-positive carriers who are still asymptomatic should establish care with a specialist (neurologist or cardiologist experienced in amyloidosis) and enter a monitoring program. Once symptoms begin, treatment should start promptly — the existing therapies stabilize but do not reverse established damage. Tafamidis is currently the mainstay of treatment for cardiomyopathy; patisiran or inotersen are used for polyneuropathy. Newer agents (vutrisiran, eplontersen) offer improved dosing convenience.

Interactions

The Val30Met variant's amyloid deposition is modulated by modifier factors not yet captured as single SNPs. The TTR tetramer stabilizer tafamidis works equally across genotypes by stabilizing all TTR tetramers regardless of which subunits carry the Val30Met mutation, making drug-gene interaction simple: carriers benefit, non-carriers do not have TTR amyloid disease to treat.

The Val142Ile variant (rs76992529)¹²¹² Val142Ile variant (rs76992529)
Also called V122I; found in ~3-4% of African Americans and the dominant cause of late-onset cardiac amyloidosis in that population is a distinct TTR mutation causing predominantly cardiac hATTR. No documented gene-gene interaction exists between Val30Met and Val142Ile — these are independent, ancestry-specific mutations in the same gene.

Family testing is especially important. Each child of a Val30Met carrier has a 50% chance of inheriting the mutation. Predictive genetic testing of at-risk adult family members enables surveillance initiation before symptoms, which is when treatment benefit is greatest.

Your bones are living tissue, constantly remodeling themselves in response to stress, hormones, and nutrition. At the heart of this process is the Wnt signaling pathway¹¹ Wnt signaling pathway
a critical cellular communication system that tells bone-forming cells (osteoblasts) when to build new bone. LRP5 (low-density lipoprotein receptor-related protein 5) acts as a co-receptor in this pathway, working alongside Frizzled proteins to transmit Wnt signals into bone cells. The A1330V variant changes a single amino acid at position 1330 from alanine (the common version) to valine (the variant), subtly altering how effectively LRP5 can do its job.

This isn't a defect — it's a natural variation that exists in populations worldwide. About 68% of people have two copies of the alanine version (CC), 24% carry one copy of each (CT), and 3% have two copies of the valine version (TT)²² 68% of people have two copies of the alanine version (CC), 24% carry one copy of each (CT), and 3% have two copies of the valine version (TT). The variant is notably more common in East Asian populations (~26% T allele frequency) than in European populations (~11%).

The Mechanism

The A1330V substitution occurs in exon 18 of the LRP5 gene, within one of the protein's four β-propeller motifs³³ β-propeller motifs
repeating structural elements where most LRP5 ligands bind. Laboratory studies have shown that when cells express the valine version of LRP5, Wnt signaling activity is significantly reduced compared to the alanine version⁴⁴ Wnt signaling activity is significantly reduced compared to the alanine version. Specifically, when researchers transfected cells with LRP5-1330V and activated Wnt signaling, the downstream TCF-Lef transcription activity — the endpoint that turns on bone-building genes — was measurably lower than in cells with normal LRP5.

This dampened signaling means osteoblasts receive a weaker "build bone" message throughout your life. The effect is modest but cumulative: each copy of the T allele is associated with approximately 0.02 g/cm² lower bone mineral density at the lumbar spine⁵⁵ approximately 0.02 g/cm² lower bone mineral density at the lumbar spine, translating to roughly 2-3% lower peak bone mass in TT individuals compared to CC.

The Evidence

The link between rs3736228 and bone health has been replicated extensively. A 2008 Bayesian meta-analysis pooling 16,705 individuals from 10 studies⁶⁶ 2008 Bayesian meta-analysis pooling 16,705 individuals from 10 studies
Tran et al. Association between LRP5 polymorphism and bone mineral density: a Bayesian meta-analysis. BMC Med Genet, 2008 found that people with the CC genotype had significantly higher lumbar spine BMD (mean difference 0.018 g/cm², 95% CI: 0.008-0.028) and femoral neck BMD than those with CT or TT genotypes. The association was consistent across ethnic groups, though effect sizes varied slightly.

More critically, the T allele increases fracture risk. A 2014 meta-analysis of seven case-control studies⁷⁷ 2014 meta-analysis of seven case-control studies
Xu et al. Common polymorphism in the LRP5 gene may increase the risk of bone fracture and osteoporosis. Biomed Res Int, 2014 found T allele carriers had a 30% increased risk of osteoporosis and fractures under most genetic models (OR ~1.3, p<0.01). The effect was seen in both Asian and Caucasian populations.

A landmark 2008 GWAS of over 30,000 individuals⁸⁸ landmark 2008 GWAS of over 30,000 individuals
Richards et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet, 2008 identified rs3736228 as one of the strongest genetic associations with BMD genome-wide, with the T allele reducing lumbar spine BMD (p = 2.6×10⁻⁹) and femoral neck BMD (p = 5.0×10⁻⁶). This wasn't a subtle effect buried in the data — it was one of the most significant signals in the entire genome.

Practical Implications

If you carry one or two copies of the T allele, you're starting with a slightly lower genetic ceiling for bone density. This doesn't doom you to fractures — peak bone mass is only about 60-80% heritable, with lifestyle factors accounting for the rest⁹⁹ peak bone mass is only about 60-80% heritable, with lifestyle factors accounting for the rest. But it does mean you have less margin for error and should prioritize bone health throughout your life, not just after menopause or in old age.

The most modifiable factors are calcium and vitamin D intake, weight-bearing exercise, and avoiding smoking and excessive alcohol¹⁰¹⁰ weight-bearing exercise, and avoiding smoking and excessive alcohol. Calcium provides the raw material for bone, vitamin D enables its absorption, and mechanical stress from exercise stimulates osteoblasts to build bone. The A1330V variant doesn't change how your body responds to these interventions — it just means you need to be more diligent about them.

Interestingly, the effect of this variant may depend on your activity level. The Odense Androgen Study of 783 young men¹¹¹¹ Odense Androgen Study of 783 young men
Saarinen et al. Polymorphisms in the LRP5 gene are associated with peak bone mass in non-sedentary men. Calcif Tissue Int, 2007 found that the A1330V polymorphism was only associated with lower BMD in physically active men, not sedentary men. This suggests the variant may alter how bones respond to mechanical loading¹²¹² the variant may alter how bones respond to mechanical loading, making exercise even more critical if you carry the T allele. A study in Japanese male workers¹³¹³ study in Japanese male workers
Nakamura et al. A1330V polymorphism and bone mineral density in Japanese male workers. Environ Health Prev Med, 2011 found that VV individuals had significantly lower BMD than AA, but exercise (past or current) was independently protective even in those with genetic susceptibility.

For postmenopausal women with the T allele, consider discussing bone density screening (DEXA scan) earlier than standard guidelines suggest¹⁴¹⁴ bone density screening (DEXA scan) earlier than standard guidelines suggest, perhaps starting in your 50s rather than 65. Early identification of low bone mass allows intervention before fractures occur.

Interactions

LRP5 doesn't act alone in determining bone health. Another common variant in the same gene, rs4988321 (V667M), also affects BMD and fracture risk¹⁵¹⁵ rs4988321 (V667M), also affects BMD and fracture risk and is often inherited together with A1330V in certain populations. The two variants may have additive effects on bone density.

Beyond LRP5, genetic variants in genes like SOST (which produces sclerostin, an inhibitor of Wnt signaling), VDR (the vitamin D receptor), and COL1A1 (type I collagen, the main structural protein in bone) also influence bone health. The cumulative effect of multiple genetic variants likely explains why some people develop severe osteoporosis while others maintain strong bones into old age.

Heart muscle cells endure relentless mechanical force with every beat — roughly 100,000 contractions per day. Holding adjacent cells together at sites of peak stress are desmosomes¹¹ desmosomes
protein complexes that act as molecular rivets between cardiac muscle cells, and desmoplakin (DSP) is their central load-bearing component. The Gln1277Ter variant — a C-to-T change at genomic position chr6:7,580,019 — introduces a premature stop codon that truncates the DSP protein at amino acid 1277, eliminating the entire C-terminal domain responsible for anchoring intermediate filaments to the desmosomal plaque. Cells carrying this truncated protein cannot maintain adhesion under mechanical load.

The Mechanism

The c.3829C>T substitution converts codon 1277 from glutamine (CAA) to a stop codon (TAA), producing either a truncated 1276-amino-acid protein or triggering nonsense-mediated mRNA decay²² nonsense-mediated mRNA decay
a cellular quality-control process that degrades mRNAs with premature stop codons, often eliminating the protein entirely. Either outcome results in desmoplakin haploinsufficiency — roughly half the normal desmoplakin output from a single functional copy. Under the mechanical stress of cardiac contraction, DSP-haploinsufficient cardiomyocytes show a 75% adhesion failure rate versus 8% in controls (P<0.001)³³ DSP-haploinsufficient cardiomyocytes show a 75% adhesion failure rate versus 8% in controls (P<0.001), with individual cells detaching from their neighbors. The consequence is fibrosis — the heart patches torn adhesion junctions with scar tissue — and a pro-arrhythmic substrate of patchy LV fibrosis that can trigger dangerous ventricular rhythms even before systolic function deteriorates.

DSP-related arrhythmogenic cardiomyopathy (DSP-ACM) differs clinically from classical arrhythmogenic right ventricular cardiomyopathy (ARVC). In a landmark study of 107 DSP-mutation carriers, 55% showed exclusive left ventricular involvement compared with 0% of PKP2-mutation carriers⁴⁴ 55% showed exclusive left ventricular involvement compared with 0% of PKP2-mutation carriers — an almost diametrically opposite distribution. Episodes resembling acute myocarditis (chest pain, troponin rise, ST changes) occur in 15–39% of carriers, often as the first clinical presentation, and can recur. These episodes accelerate fibrosis and significantly raise subsequent arrhythmia and heart failure risk.

The Evidence

Three large recent studies have defined the clinical burden. Gasperetti et al. (European Heart Journal, 2025)⁵⁵ Gasperetti et al. (European Heart Journal, 2025) followed 800 DSP pathogenic variant carriers and documented sustained ventricular arrhythmia in 17.4% of the cohort (3.9% per year). A striking 32.5% of carriers did not meet established diagnostic criteria for any cardiomyopathy subtype, underscoring how easily DSP-ACM is missed by standard workups. Myocardial injury episodes — the myocarditis-like flares — were associated with a 2.4-fold increase in ventricular arrhythmia risk and a 5.1-fold increase in heart failure hospitalizations.

Hoorntje et al. (Circ Genomic Precis Med, 2023)⁶⁶ Hoorntje et al. (Circ Genomic Precis Med, 2023) studied 170 individuals with DSP truncating variants and found ventricular arrhythmia (sudden cardiac arrest, sustained VT, or appropriate ICD therapy) in 33%. Critically, they showed that variants in positions subject to nonsense-mediated decay — which the Gln1277Ter variant likely is, given its location in exon 23 of 24 — were significantly more arrhythmogenic than truncating variants that escape decay and produce a stable truncated protein. Variant location is now recognized as an independent risk stratification tool.

Lota et al. (Circulation, 2022)⁷⁷ Lota et al. (Circulation, 2022) found DSP truncating variants in 3.1% of acute myocarditis patients versus 0.4% of healthy controls (OR 8.2, P=0.001). Five-year all-cause mortality was 11.1% for genotype-positive myocarditis patients versus 3.3% for genotype-negative — nearly a 3.5-fold difference.

Practical Actions

Heterozygous carriers of this variant require cardiac surveillance even in the absence of symptoms. The standard approach includes baseline cardiac MRI with late gadolinium enhancement (the primary tool for detecting early fibrosis), Holter monitoring, and genetic cascade testing for first-degree relatives. Vigorous competitive athletics is generally discouraged pending formal cardiological assessment, as high mechanical cardiac stress may precipitate adhesion failure. Episodes of chest pain, palpitations, or unexplained troponin elevation in a carrier should be evaluated urgently as possible myocarditis-like events, not dismissed as common causes.

Interactions

DSP-ACM risk is modified by other desmosomal gene variants. Compound heterozygosity — carrying pathogenic variants in two different desmosomal genes (e.g. DSP + PKP2, DSP + DSG2, or DSP + JUP) — is associated with earlier onset and more severe disease in clinical series. Carriers of this DSP variant who also carry variants in PKP2 (rs111517471) or DSG2 (rs397516946) may warrant particularly aggressive surveillance protocols. These interactions should be assessed by a specialist in inherited cardiomyopathies. Physical activity level appears to act as an environmental modifier: endurance athletes with desmosomal variants develop cardiomyopathy at substantially higher rates than sedentary carriers.

Apolipoprotein B (ApoB) is far more than a cardiovascular protein. While ApoB-100 is best known as the structural backbone of LDL particles¹¹ LDL particles
each LDL particle carries exactly one ApoB-100 molecule, making ApoB a direct count of atherogenic particles, ApoB also plays a central role in bile acid metabolism and biliary lipid secretion. The liver exports cholesterol into bile via ABCG5/G8 transporters, but the hepatic lipid pools that feed bile production are regulated upstream by ApoB-containing lipoprotein trafficking. Variants that alter APOB regulation or expression can therefore shift biliary lipid balance — with consequences that extend beyond the arteries to the bile ducts and gallbladder.

The rs520354 variant sits 360 nucleotides into intron 6 of APOB (IVS6+360), deep within a non-coding region. It does not change any amino acid. Yet a large population-based study in China identified a striking sex-specific association: men carrying the A allele — the more common allele globally — faced roughly twice the risk of extrahepatic bile duct cancer compared to men carrying only G alleles.

The Mechanism

Because rs520354 is intronic, it does not alter the ApoB protein directly. Intronic variants can influence phenotype through several routes: altered pre-mRNA splicing²² pre-mRNA splicing
changes in exon inclusion/exclusion alter the final protein produced, creation or disruption of intronic regulatory elements, or linkage disequilibrium with a nearby causal variant in the same haplotype block. The IVS6+360 region falls within an intronic stretch with predicted regulatory motifs, and the A-allele haplotype (tagging the T allele in coding-strand notation) may tag a regulatory change that subtly shifts hepatic ApoB expression or biliary lipid composition.

Sex-specificity suggests hormonal interaction. Estrogen stimulates biliary cholesterol secretion and can raise the ratio of cholesterol-to-bile-salt in bile — a lithogenic³³ lithogenic
bile that tends to form gallstones because of high cholesterol saturation relative to bile acids and phospholipids index that promotes gallstone formation. In men, where estrogen is absent as a dominant modulator, any genetic shift in ApoB-mediated hepatic lipid handling may unmask differently than in women, where estrogen effects dominate biliary lipid composition. The APOB haplotype T-T (combining IVS6+360 and EX4+56 coding-strand T alleles) showed an even stronger bile duct cancer association (OR 1.6, 95% CI 1.1–2.3), consistent with haplotype effects in the same regulatory region.

The Evidence

The primary evidence comes from a 2008 population-based case-control study⁴⁴ 2008 population-based case-control study
Andreotti G et al., Cancer Epidemiol Biomarkers Prev, 17(3):525-34 conducted in Shanghai, China, comparing 235 gallbladder cancer cases, 125 extrahepatic bile duct cancer cases, 46 ampullary cancer cases, and 880 biliary stone cases against 779 population controls. Male carriers of the IVS6+360 T allele (A allele on the plus strand) had an odds ratio of 2.0 (95% CI 1.2–3.4) for bile duct cancer. This sex-specific association was not significant in women, and there was no significant association with gallbladder cancer or biliary stones overall, though the bile duct cancer finding was replicated when the full APOB haplotype was included.

A companion 2009 lipid study⁵⁵ 2009 lipid study
Andreotti G et al., Eur J Epidemiol, 24(12):763-74 examined APOB variants and serum lipid levels in 799 healthy Chinese residents and did not find rs520354 to be significantly associated with total cholesterol, LDL, or ApoB levels — suggesting this variant's primary effect in the biliary context is independent of gross changes in circulating lipids.

The evidence level is moderate: this is a single large case-control study with a biologically plausible sex-specific effect, but the finding requires replication in non-Chinese populations. The intronic mechanism remains hypothetical. ClinVar classifies this variant as benign in the context of hereditary lipid disorders, consistent with its lack of effect on serum lipids — the biliary cancer risk signal is a distinct phenotype not captured in that classification.

Practical Actions

For men carrying the A allele (AA or AG genotype), the actionable implication is heightened awareness of biliary tract health. The elevated risk is for extrahepatic bile duct cancer specifically — a relatively uncommon malignancy but one with poor prognosis when detected late. Men with this genotype who also have other biliary risk factors (gallstones, primary sclerosing cholangitis, chronic biliary infection, obesity, or heavy alcohol use) face a compounded risk that warrants proactive monitoring. Dietary modification that reduces biliary cholesterol saturation — specifically limiting dietary cholesterol and increasing bile acid–binding fiber — may reduce lithogenic stress on the bile ducts regardless of cancer risk.

Interactions

The IVS6+360 A allele appears to act as part of an APOB haplotype with the EX4+56 C>T variant. Carriers of the full T-T haplotype (both variants on the coding strand) had stronger bile duct cancer associations than IVS6+360 alone — suggesting additive effects within the same gene. The related rs693⁶⁶ rs693
APOB XbaI, a synonymous exon 26 variant with well-established effects on LDL particle number and ApoB levels represents a second independent functional locus in APOB with cardiovascular rather than biliary effects; the two should not be confused. APOE variants (particularly APOE rs440446) showed even stronger sex-specific biliary cancer associations in the same Shanghai study — suggesting a broader pattern of ApoB pathway variants influencing biliary tract cancer risk through partially overlapping mechanisms.

Bacteria don't invade quietly. The moment a triacylated lipopeptide from a mycobacterium, spirochete, or gram-positive organism reaches your innate immune cells, it should trigger a rapid response — but only if Toll-Like Receptor 1 (TLR1)¹¹ Toll-Like Receptor 1 (TLR1)
TLR1 is a pattern-recognition receptor that forms heterodimers with TLR2 to detect bacterial triacylated lipopeptides such as those from Mycobacterium tuberculosis and M. leprae has reached the cell surface. The rs5743618 I602S variant (c.2079T>G, historically labeled 1805T>G) disrupts a transmembrane trafficking motif at the boundary between TLR1's transmembrane and intracellular domains, trapping the receptor inside the cell rather than displaying it on the surface.

The evolutionary history of this variant is striking. The serine-602 (S) allele, which impairs TLR1 surface expression, shows clear signatures of positive selection²² clear signatures of positive selection
iHS and XP-EHH statistics in the 1000 Genomes populations in European populations and is found in approximately 75% of Europeans — making intact (isoleucine-602) TLR1 the minority form in Europe. The allele is far less common in African (~25%) and East Asian (~2%) populations, suggesting it was selected for in environments where dampening TLR1 signaling conferred a survival advantage, possibly by reducing immunopathology from chronic bacterial and mycobacterial exposure.

The Mechanism

TLR1 and TLR2 form obligate heterodimers to recognize bacterial triacylated lipopeptides (tri-acyl LP)³³ bacterial triacylated lipopeptides (tri-acyl LP)
lipoproteins with three fatty acid chains found on mycobacteria, borreliae, and gram-positive bacteria — structurally distinct from the diacylated lipopeptides recognized by TLR2/TLR6 heterodimers. When TLR1/TLR2 binds its ligand, the intracellular TIR domains recruit MAL and MyD88 and activate NF-κB, producing TNF-α, IL-6, IL-12, and other pro-inflammatory cytokines essential for bacterial killing.

The I602S substitution places a serine — a hydroxyl-bearing, polar amino acid — at position 602 in the transmembrane domain, where the hydrophobic isoleucine is required for proper folding and export. The result: TLR1 protein is produced normally but retained intracellularly⁴⁴ retained intracellularly
individuals homozygous for 602S completely lack cell-surface TLR1 while retaining normal intracellular TLR1 protein levels. Without surface expression, TLR1/TLR2 heterodimers cannot form efficiently, and NF-κB activation by triacylated lipopeptides is severely blunted⁵⁵ NF-κB activation by triacylated lipopeptides is severely blunted
whole-blood TNF-α production after Pam3CSK4 stimulation is markedly reduced in 602S homozygotes.

A key mechanistic nuance: this variant exclusively disrupts TLR1-dependent signaling. TLR2/TLR6 heterodimer signaling (recognizing diacylated lipopeptides) is unaffected. This means the immune system is selectively blunted for one arm of bacterial lipopeptide recognition while the other remains intact.

The Evidence

Leprosy provided the first strong human association. Johnson et al. (2007) showed the 602S allele protects against clinical leprosy⁶⁶ protects against clinical leprosy
OR 0.48 in Turkish case-control, with 602S homozygotes predominantly in the healthy control group. A larger Indian case-control replication across two cities (New Delhi and Kolkata) confirmed this with a combined P = 5.7×10⁻⁸, OR = 0.31⁷⁷ combined P = 5.7×10⁻⁸, OR = 0.31
one of the strongest associations ever reported for an innate immune variant and an infectious disease. The paradox: reduced TLR1 signaling protects against leprosy by limiting mycobacteria-driven tissue damage and the Th1 immunopathology that drives the severe lepromatous form.

Tuberculosis shows the inverse. When TLR1 is active (602I/A allele), it helps defend against mycobacteria. A Han Chinese pediatric study⁸⁸ Han Chinese pediatric study
206 TB cases and 201 healthy controls found the A (602I) allele associated with increased TB risk (OR 2.40, 95%CI 1.41–4.07, P = 0.0009). A separate Brazilian cohort (Amazonas state) found that heterozygous 1805TG individuals were overrepresented among multibacillary vs paucibacillary TB⁹⁹ heterozygous 1805TG individuals were overrepresented among multibacillary vs paucibacillary TB
OR 3.72 for multibacillary disease — consistent with heightened TLR1 signaling driving the granulomatous response and immune pathology of more severe disease. These findings are not entirely consistent across all meta-analyses, suggesting population-specific and disease-stage-specific effects.

Sepsis reveals an additional dimension. In the intensive care setting, the 602I (A allele) confers enhanced neutrophil priming by Pam3CSK4¹⁰¹⁰ neutrophil priming by Pam3CSK4
TLR2/1 agonist: elevated ROS generation, MAPK phosphorylation, integrin activation, and cytokine secretion. In a pediatric sepsis cohort, children homozygous for the 602I genotype had a prolonged PICU length of stay, suggesting that overly active TLR1-mediated neutrophil responses may amplify organ damage in sepsis.

Post-infectious Lyme arthritis is the most recently described association. A 2025 study found that patients with TLR1 1805GG (602I/602I)¹¹¹¹ TLR1 1805GG (602I/602I)
the AA genotype on plus strand were significantly overrepresented among patients who developed persistent post-infectious Lyme arthritis after antibiotic treatment. In PBMCs with this genotype, repeated Borrelia burgdorferi stimulation failed to induce innate immune tolerance — resulting in unabated cytokine production even after bacterial clearance — consistent with the sustained joint inflammation seen in this condition.

Practical Implications

This variant sits at a meaningful evolutionary trade-off: the 602S allele (reduced TLR1 surface expression) was positively selected in European populations — likely because a dampened TLR1/TLR2 response reduces immunopathology in chronic mycobacterial exposure. But this selection came with a cost: less effective early bacterial clearance in some infection contexts, particularly for individuals who are AA (602I/602I) or have one active copy (AC), who face an inverted risk landscape.

For users carrying the A allele (602I, full TLR1 surface expression): the practical significance depends heavily on exposure context. In low-leprosy environments, having intact TLR1 is generally an asset for bacterial defense. The Lyme arthritis finding deserves attention for those in tick-endemic regions.

For CC (602S/602S) users: TLR1 surface expression is absent, reducing bacterial triacylated lipopeptide recognition. In populations where leprosy and severe mycobacterial disease are rare, this is largely a neutral-to-protective state. Standard infection prevention measures apply.

Interactions

TLR1 forms obligate heterodimers with TLR2 (rs5743708) for triacylated lipopeptide recognition. The TLR2 R753Q variant independently impairs TLR2 signaling, and in a Colombian case-control study, the haplotype combining rs5743618, rs5743708 (TLR2 R753Q), and rs5743810 (TLR6 Ser249Pro) was associated with altered leprosy susceptibility — suggesting additive effects across the TLR1/2/6 trimer complex. Carriers of both TLR1 A allele (602I) and TLR2 A allele (753Q) would likely face compounded reductions in combined TLR1/TLR2 output via independent mechanisms.

TLR6 (rs5743810) pairs with TLR2 to recognize diacylated lipopeptides — the functional partner on the other side. TLR4 (rs4986790) handles gram-negative LPS independently. Innate immune profiling across TLR1, TLR2, TLR4, TLR6, and TLR9 variants provides the most complete picture of bacterial recognition capacity.

The FUT2 gene encodes fucosyltransferase 2¹¹ fucosyltransferase 2
An enzyme that adds fucose sugar residues to glycan chains on cell surfaces and in secreted mucus, an enzyme that determines one of the most fundamental divisions in human biology: whether you are a "secretor" or a "non-secretor." Secretors express ABO blood group antigens²² ABO blood group antigens
The same A, B, and H antigens that define your blood type (A, B, AB, O), but expressed on mucosal surfaces and in saliva, tears, breast milk, and intestinal mucus rather than just on red blood cells on their mucosal surfaces and in bodily fluids like saliva and intestinal mucus. Non-secretors do not.

A single G-to-A change at position 428 of the FUT2 coding sequence creates a premature stop codon (Trp143Ter), completely inactivating the enzyme. People with two copies of the A allele — about 20% of Europeans — produce no functional FUT2 and are non-secretors. This is one of the most pleiotropic³³ pleiotropic
Affecting multiple, seemingly unrelated traits from a single genetic variant common variants in the human genome, influencing gut microbiome composition, vitamin B12 metabolism, susceptibility to viral infections, and risk of autoimmune disease.

The Mechanism

FUT2 adds fucose⁴⁴ fucose
A six-carbon sugar (6-deoxy-L-galactose) that serves as a building block for complex sugar chains on cell surfaces to glycan structures on the intestinal epithelium and in mucosal secretions, creating the H antigen — the precursor to A and B blood group antigens. In secretors, these fucosylated glycans coat the gut lining and are shed into the intestinal lumen, where they serve two critical functions.

First, they act as attachment points for certain pathogens. Norovirus and rotavirus bind to H-type and Lewis blood group antigens on intestinal cells to initiate infection. Without these glycans, the viruses literally cannot gain a foothold. Second, the shed fucosylated glycans serve as a carbon source for beneficial gut bacteria, particularly Bifidobacterium⁵⁵ Bifidobacterium
A genus of beneficial bacteria that are among the first colonizers of the infant gut and remain important for intestinal health throughout life species, which have evolved specialized enzymes to harvest fucose from host glycans.

The W143X nonsense mutation truncates the FUT2 protein at amino acid 143 (of 332 total), eliminating the catalytic domain entirely. Heterozygous carriers (AG) retain secretor status because one functional copy produces sufficient enzyme, though possibly at somewhat reduced levels.

The Evidence

The landmark norovirus study⁶⁶ landmark norovirus study
Thorven M et al. A homozygous nonsense mutation (428G→A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J Virol, 2005 demonstrated that among 115 Swedish adults exposed to norovirus outbreaks, not a single non-secretor (AA genotype) developed symptomatic infection, while 49% of GG homozygotes and 51% of AG heterozygotes were affected. A 2021 meta-analysis of 20 studies⁷⁷ 2021 meta-analysis of 20 studies
Bustamante M et al. FUT2 and norovirus: a systematic review and meta-analysis confirmed that non-secretors are approximately 3 times more likely to remain uninfected during norovirus exposure.

For vitamin B12, a genome-wide association study⁸⁸ genome-wide association study
Hazra A et al. Common variants of FUT2 are associated with plasma vitamin B12 levels. Nat Genet, 2008 identified FUT2 as the strongest genetic determinant of plasma B12 levels (p = 5.36 x 10^-17). Paradoxically, non-secretors have 16-18% higher measured serum B12⁹⁹ 16-18% higher measured serum B12
Velkova A et al. The FUT2 secretor variant p.Trp154Ter influences serum vitamin B12 concentration via holo-haptocorrin. Hum Mol Genet, 2017. However, this elevation is in haptocorrin-bound B12¹⁰¹⁰ haptocorrin-bound B12
Haptocorrin (also called transcobalamin I) is a B12 carrier protein in blood that is not readily taken up by cells. It is distinct from transcobalamin II, which delivers B12 to tissues — a biologically inactive fraction — rather than in holotranscobalamin¹¹¹¹ holotranscobalamin
The portion of blood B12 bound to transcobalamin II, which is the only form that can be actively taken up by cells and used for metabolic reactions, the bioavailable form. This means standard total B12 blood tests may overestimate functional B12 status in non-secretors.

The Crohn's disease link¹²¹² Crohn's disease link
McGovern DPB et al. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Hum Mol Genet, 2010 was established through GWAS, with non-secretors showing increased susceptibility (OR ~1.64 for AA genotype). A separate study¹³¹³ separate study
Smyth DJ et al. FUT2 nonsecretor status links type 1 diabetes susceptibility and resistance to infection. Diabetes, 2011 found that the AA genotype also confers susceptibility to type 1 diabetes (OR 1.29, 95% CI 1.20-1.37, p = 4.3 x 10^-18). The proposed mechanism links altered gut microbiome composition to immune dysregulation.

The gut microbiome connection¹⁴¹⁴ gut microbiome connection
Wacklin P et al. Secretor genotype (FUT2 gene) is strongly associated with the composition of bifidobacteria in the human intestine. PLoS One, 2011 showed that non-secretors harbor significantly lower diversity and abundance of Bifidobacterium species. Without fucosylated glycans lining the gut, these beneficial bacteria lose a primary food source, potentially contributing to the gut dysbiosis that underlies the increased Crohn's and autoimmune risk.

Practical Implications

The effects of FUT2 secretor status are a striking example of evolutionary trade-offs. Non-secretors gain robust protection against norovirus (and likely rotavirus and some bacterial pathogens) at the cost of a less diverse gut microbiome and modestly increased risk of certain autoimmune conditions.

For non-secretors (AA), the most actionable implications involve gut health maintenance and vitamin B12 monitoring. Since standard serum B12 tests may be misleadingly normal, requesting a holotranscobalamin (active B12) or methylmalonic acid test provides a more accurate picture of functional B12 status. Supporting gut bifidobacterial populations through targeted probiotics and prebiotic fiber is also worth considering, given the reduced diversity seen in non-secretors.

For heterozygous carriers (AG), secretor function is preserved and no specific action is typically needed, though being aware of this variant's role in B12 metabolism can inform supplement choices.

Interactions

FUT2 secretor status interacts with ABO blood type. The A and B antigens are built on top of the H antigen that FUT2 creates — so non-secretors do not express A, B, or H antigens in their mucus regardless of their ABO blood type. This means ABO-mediated disease associations on mucosal surfaces (such as susceptibility to H. pylori) can be modified by FUT2 status.

The variant rs602662 (S258G) and rs492602 are in strong linkage disequilibrium with rs601338 and show similar associations with B12 levels and disease risk. In East Asian populations, a different FUT2 variant (rs1047781, A385T) is the primary determinant of secretor status, since the W143X variant is nearly absent in that population (allele frequency <0.2%).

ROS1 encodes a receptor tyrosine kinase — a membrane-spanning signalling protein that responds to extracellular cues by triggering intracellular phosphorylation cascades that govern cell growth, differentiation, and survival. Unlike its better-known oncogenic role in non-small cell lung cancer¹¹ non-small cell lung cancer
ROS1 gene fusions drive ~1–2% of NSCLC cases and are targeted by crizotinib, the germline missense variant rs619203 is a common population polymorphism affecting the kinase domain. The C allele substitutes cysteine for serine at position 2229 of the protein, a change that introduces a free thiol group in a region important for kinase regulation. This variant was first flagged in a 2005 multi-phase case-control study as one of four novel SNPs associated with myocardial infarction, but subsequent replication has been inconsistent across populations.

The Mechanism

ROS1 signals through receptor tyrosine kinase pathways²² receptor tyrosine kinase pathways
RTKs phosphorylate downstream targets including PI3K/AKT and RAS/MAPK cascades that regulate vascular smooth muscle proliferation, endothelial function, and inflammatory signalling. The Ser2229Cys substitution falls within the kinase domain of the protein. Serine at this position is a potential phosphorylation site, and its replacement by cysteine — which carries a reactive thiol side chain — could alter autophosphorylation dynamics, receptor activation threshold, or substrate specificity. Because ROS1 is expressed at low levels in cardiac and vascular tissue, the proposed mechanism is that subtle perturbations in RTK-mediated vascular signalling cumulatively influence atherothrombotic plaque vulnerability or endothelial inflammatory tone rather than causing a dramatic, easily measurable biochemical phenotype.

The Evidence

The association between rs619203 and cardiovascular risk originated with Shiffman et al. 2005³³ Shiffman et al. 2005
Shiffman D et al. Identification of four gene variants associated with myocardial infarction. Am J Hum Genet. 2005;77(4):596-605, who conducted three sequential case-control studies totalling approximately 1,345 MI cases and 1,843 controls. They reported an OR of 1.75 for individuals homozygous for two risk alleles compared to non-carriers, with consistent directional effects across the three study phases. This was a significant initial signal in the era before large-scale GWAS.

Subsequent replication has been mixed. A Japanese association study of 3,432 individuals found the G→C polymorphism (Cys2229Ser) significantly associated with atherothrombotic cerebral infarction⁴⁴ significantly associated with atherothrombotic cerebral infarction
Yamada Y et al. Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals. Stroke. 2008;39(8):2211-8, extending the cardiovascular signal to stroke. A Siberian study of 200 MI patients and 420 controls also confirmed the association and noted a link between rs619203 genotype and fasting glucose levels, suggesting a metabolic component.

However, several European replication attempts have failed. A German study of 3,657 MI cases and 1,211 controls found no significant difference in allele frequencies between MI patients and controls⁵⁵ no significant difference in allele frequencies between MI patients and controls
Koch W et al. Variations of specific non-candidate genes and risk of myocardial infarction. Int J Cardiol. 2011;148(3):339-44 (p≥0.25). A Russian cohort of young MI patients (<45 years) also found no significant association. These failures to replicate suggest either population-specific effects or that the initial signal reflected linkage to a causal variant not directly captured by rs619203. The overall evidence base qualifies this as emerging — insufficient for clinical use but biologically plausible.

Practical Actions

For CC homozygotes — who carry two copies of the Cys2229 allele and represent about 6% of people globally — monitoring of cardiovascular risk factors makes sense given the available signal, even without definitive clinical-grade evidence. The C allele frequency is highest in Europeans (~26%) and lowest in Africans (~8%), meaning the risk population is predominantly of European or East Asian ancestry. Standard cardiovascular biomarkers (hs-CRP, LDL, Lp(a)) and blood pressure tracking provide the most actionable handles for this genotype while the scientific evidence matures.

Interactions

rs619203 was initially identified alongside three other MI-associated SNPs in the same discovery study, including variants near rs499818. In the Siberian replication cohort, the strongest independent MI predictors were rs1333049 (9p21 locus) and rs10757278 (also 9p21), both of which showed more robust replication than rs619203. The 9p21 locus variants are well-established MI risk factors, and their co-presence with rs619203 in studies may represent confounding or additive — rather than synergistic — effects.

The serotonin 2A receptor gene (HTR2A) encodes one of the brain's most important receptors for serotonin signaling¹¹ serotonin signaling
Serotonin (5-HT) is a neurotransmitter involved in mood regulation, sleep, appetite, and cognition. The 5-HT2A receptor is a primary target for many antidepressants and antipsychotics.. The rs6311 polymorphism sits in the promoter region of this gene, 1438 bases upstream of the transcription start site, where it influences how much receptor protein your cells produce. This variant has been extensively studied for its role in psychiatric medication response²² psychiatric medication response
Over 149 publications have investigated this SNP in relation to mental health conditions and treatment response, though results have been notably inconsistent for efficacy and more consistent for side effects.

The Mechanism

Rs6311 is a regulatory variant³³ regulatory variant
Located in the promoter/5' UTR region, this SNP affects transcriptional regulation rather than changing the protein sequence directly that modulates HTR2A gene expression. The variant is transcribed in minor isoforms of HTR2A mRNA, particularly those with an extended 5' untranslated region (UTR). Research shows the A allele associates with reduced expression⁴⁴ A allele associates with reduced expression
The variant "A" allele of rs6311 is associated with reduced expression of isoforms containing the extended 5' UTR of these extended UTR isoforms. The G allele, conversely, allows higher expression of the extended 5' UTR, which may increase translational efficiency and ultimately receptor density in the brain.

Rs6311 exists in near-perfect linkage disequilibrium⁵⁵ near-perfect linkage disequilibrium
Rs6311 and rs6313 are in near-perfect LD, located 1538 bases apart on chromosome 13, with 99.6-99.7% concordance between alleles with rs6313 (T102C), a synonymous coding variant. In most cases, the rs6311 G allele pairs with rs6313 C, and rs6311 A pairs with rs6313 T. This tight linkage makes it difficult to determine which variant drives observed effects, though functional studies suggest rs6311's regulatory location may be more mechanistically relevant.

The Evidence

The most robust and replicated finding for rs6311 concerns SSRI side effects rather than efficacy. A weighted average of three paroxetine studies⁶⁶ weighted average of three paroxetine studies
All three studies (total n = 237) found significantly increased incidence of adverse events in patients with the -1438GG genotype, with side effect rates increasing from 15% among A carriers to 42% among GG homozygotes (n=237 total) showed side effect rates of 15% among A allele carriers versus 42% among GG homozygotes when treated with paroxetine. Similar patterns have been observed with other SSRIs including citalopram and fluvoxamine, though these findings await replication in larger cohorts.

In a Malay population study⁷⁷ Malay population study
The GG genotype of HTR2A polymorphism has decreased odds for dizziness but increased odds for poor concentration, while GA genotype increases odds for excessive sweating, diarrhea, constipation and blurred vision, the GG genotype showed decreased odds for dizziness but increased odds for poor concentration, while the GA genotype increased odds for excessive sweating, diarrhea, constipation, and blurred vision on SSRI treatment. A 2019 study on sexual dysfunction⁸⁸ 2019 study on sexual dysfunction
The -1438A/G and 102T/C polymorphisms appear associated with sexual dysfunction induced by citalopram, with risk increasing with number of "risky" alleles found that sexual dysfunction risk from citalopram/sertraline increased with the number of "risky" alleles (G for rs6311, C for rs6313, L for 5-HTTLPR).

Evidence for treatment efficacy is considerably less consistent. A large Chinese study⁹⁹ large Chinese study
Study of 290 patients treated with SSRIs found no association between rs6311 and treatment response or remission (n=290) found no association with SSRI response or remission. The STAR*D study, one of the largest antidepressant trials, also found no significant association¹⁰¹⁰ also found no significant association
Neither rs6311 nor rs6313 showed significant association with treatment response or remission in the STAR*D study for rs6311 with citalopram efficacy. A 2020 meta-analysis¹¹¹¹ 2020 meta-analysis
Pooled analyses of 16 studies (1931 subjects) indicated significant association with higher response in dominant model for 1438A/G polymorphism (OR: 1.40, 95% CI: 1.12-1.76) of 42 studies found some evidence for improved response with the GG genotype, but noted results were highly dependent on individual studies and publication bias may be present.

Beyond antidepressant effects, rs6311 has been studied extensively in schizophrenia. A meta-analysis of 15 case-control studies¹²¹² meta-analysis of 15 case-control studies
The -1438A/G polymorphism was a risk factor for schizophrenia, especially in Caucasians, with odds ratios ranging from 1.12-1.20 depending on genetic model found the G allele associated with increased schizophrenia risk in Caucasian populations (OR 1.12-1.20 depending on genetic model), though not in East Asian populations, highlighting important ancestry-specific effects.

Practical Implications

If you carry the GG genotype and are prescribed an SSRI, the evidence suggests heightened vigilance for side effects is warranted. The increased side effect risk with GG is one of the more consistent pharmacogenetic findings in psychiatry, though it's important to note this reflects population averages — individual responses vary considerably. Work closely with your prescriber to monitor for common SSRI side effects including gastrointestinal disturbances, sexual dysfunction, sleep changes, and activation symptoms, especially during the first 4-6 weeks of treatment.

The inconsistent efficacy data means rs6311 shouldn't guide initial drug selection, but it may inform how aggressively to pursue alternative medications if side effects emerge. If you experience intolerable side effects on one SSRI, alternatives include trying a different SSRI class (as pharmacokinetic differences may matter more than pharmacodynamic 5-HT2A effects), considering SNRIs or other antidepressant classes, or exploring non-serotonergic options depending on your clinical presentation.

For AA genotype carriers, the lower side effect risk doesn't guarantee a problem-free experience — individual factors including dose, drug-drug interactions, and comorbidities matter enormously. The same caution applies to those with AG genotypes, who show intermediate risk in the available data.

Interactions

Rs6311 interacts closely with rs6313 due to their near-complete linkage disequilibrium. Any effects attributed to one variant likely reflect the haplotype they share. Rs7997012, another HTR2A intronic SNP, has been studied primarily for antidepressant efficacy (with more consistent results than rs6311) and may compound effects on treatment response when combined with rs6311/rs6313 variants. Rs6314 (His452Tyr), a missense variant in HTR2A, also shows linkage with rs6311 and has been associated with aggressive traits and treatment response.

Compound effects involving rs6311 AG or GG genotypes plus rs6313 and 5-HTTLPR variants appear to increase sexual dysfunction risk on SSRIs in a dose-dependent manner. A 2011 study¹³¹³ 2011 study
Interaction between rs7997012, rs6311 and gender explained 14% of variance in treatment response, suggesting rs6311 may not independently influence outcome but plays a role through interactions found the interaction between rs7997012, rs6311, and gender explained 14% of variance in treatment response, suggesting rs6311's effects may emerge primarily through interactions rather than independently.

VEGFA (Vascular Endothelial Growth Factor A) encodes the master regulator of angiogenesis¹¹ angiogenesis
The formation of new blood vessels from existing ones, essential for tissue growth and repair. While VEGFA is widely known for its role in wound healing and cancer biology, it plays a surprisingly important role in adipose tissue function. Fat tissue requires an extensive blood vessel network to function properly — and VEGFA determines how well vascularized your fat depots are.

The rs6905288 variant sits in an intronic regulatory region near VEGFA on chromosome 6. It was identified in one of the largest GWAS meta-analyses for fat distribution and shows one of the clearest examples of sexual dimorphism²² sexual dimorphism
The genetic effect on fat distribution is substantially stronger in women than in men in fat distribution genetics.

The Mechanism

Adipose tissue is one of the most highly vascularized organs in the body. When fat tissue expands, it needs new blood vessels to supply oxygen and nutrients. VEGF-A drives this process, and the balance of VEGF-A expression determines whether fat expansion is metabolically healthy or unhealthy³³ metabolically healthy or unhealthy
Well-vascularized fat tissue stores lipids safely; poorly vascularized fat becomes inflamed, fibrotic, and insulin resistant.

Research has shown dichotomous effects⁴⁴ dichotomous effects
VEGF-A can either improve or worsen adipose function depending on the level and timing of expression — moderate VEGF-A overexpression in white adipose tissue promotes healthy fat expansion with better vascularization and even a "beiging" effect (conversion toward metabolically active brown-like fat), while dysregulated VEGF-A signaling promotes pathological adipose expansion with inflammation and fibrosis.

The A allele at rs6905288 is associated with altered VEGFA regulatory activity that shifts fat distribution toward a central pattern and increases insulin resistance.

The Evidence

The Heid et al. 2010 meta-analysis⁵⁵ Heid et al. 2010 meta-analysis
Heid et al. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet, 2010 identified rs6905288 near VEGFA among 13 new loci for WHR in a meta-analysis of 32 GWAS studies comprising 77,167 participants with replication in 113,636 individuals. VEGFA was one of seven loci showing marked sexual dimorphism, with stronger effects in women.

In a metabolic phenotyping study of 6,039 Danes⁶⁶ metabolic phenotyping study of 6,039 Danes
Burgdorf et al. Association studies of novel obesity-related gene variants with quantitative metabolic phenotypes in a population-based sample of 6,039 Danish individuals. Diabetologia, 2012, female carriers of the VEGFA rs6905288 A allele showed insulin resistance with a 3.7% increase in HOMA-IR⁷⁷ HOMA-IR
Homeostatic Model Assessment for Insulin Resistance, a standard measure calculated from fasting glucose and insulin (P = 0.00036) and a 4.0% decrease in the Matsuda index⁸⁸ Matsuda index
A measure of whole-body insulin sensitivity derived from an oral glucose tolerance test (P = 2 x 10^-4).

The Shungin et al. 2015 study⁹⁹ Shungin et al. 2015 study
Shungin et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature, 2015 expanded the evidence across 224,459 individuals, confirming the VEGFA locus and specifically implicating angiogenesis as a pathway linking genetic variants to fat distribution. A subsequent Mendelian randomization analysis¹⁰¹⁰ Mendelian randomization analysis
Emdin et al. JAMA, 2017 demonstrated that WHR-raising variants are causally linked to type 2 diabetes (OR 1.77) and coronary heart disease (OR 1.46).

Practical Actions

The VEGFA variant's effect on adipose vascularization and insulin resistance suggests that supporting healthy angiogenesis in fat tissue may help mitigate the metabolic consequences. Nutrients and activities that promote healthy vascular function in adipose tissue may be particularly relevant for carriers.

Interactions

VEGFA rs6905288 interacts biologically with the VEGFA promoter variant rs2010963 (already in this database under fitness/body). While rs2010963 directly affects VEGF-A protein expression levels, rs6905288 influences the regulatory context in adipose tissue specifically. Carriers of risk alleles at both positions may have compounded effects on adipose vascularization. Additionally, the angiogenesis pathway intersects with the VEGFC variant rs11677611 in the lipedema category, since both vascular growth factors regulate the fluid and fat dynamics in adipose tissue through complementary mechanisms.